Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Core Insights - Immuneering Corporation reported a 64% overall survival rate at 12 months for first-line pancreatic cancer patients treated with atebimetinib + mGnP, significantly higher than the standard of care benchmark of 35% [1][2][3] - The company is on track to initiate the pivotal Phase 3 MAPKeeper 301 trial in mid-2026, following alignment with the FDA and EMA on trial design [1][3] - Immuneering ended 2025 with $217 million in cash and equivalents, providing a financial runway into 2029 [1][5] Clinical Developments - The ongoing Phase 2a trial of atebimetinib + mGnP showed a median follow-up of 13.4 months with a favorable safety profile, where only neutropenia and anemia were observed at grade 3 or higher in over 10% of patients [3] - The company plans to begin dosing in a Phase 2 trial of atebimetinib + Libtayo for first-line RAS-mutant non-small cell lung cancer in the second half of 2026 [1][3] Financial Performance - For Q4 2025, research and development expenses were $9.3 million, down from $14.9 million in Q4 2024, while full-year R&D expenses decreased to $42 million from $48 million [8] - General and administrative expenses for Q4 2025 increased to $4.5 million from $3.7 million in Q4 2024, with full-year G&A expenses rising to $17.3 million from $16.1 million [8] - The net loss for Q4 2025 was $11.6 million, or $0.18 per share, compared to a net loss of $18.1 million, or $0.58 per share, in Q4 2024 [8] Strategic Positioning - Immuneering's lead product candidate, atebimetinib, is a Deep Cyclic Inhibitor targeting MEK, designed to improve survival across various cancer types, particularly those driven by the MAPK pathway [6][9] - The company has a solid pipeline and is well-positioned to advance its mission of improving patient outcomes in oncology [2][9]